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Uszkodzenia DNA takie jak oksydacyjnie
zmodyfikowane zasady i nUkleotydy, Sq
przy sprawnych systemach naprawy wy-
cinane i bez dalszych zmian meta-
bolicznych wydzielane do moczu.
Cefe pracy: 1. Analiza zawartosci
8-oksy-2' -deoksyguanozyny i 8-oksy-
guaniny w moczu pacjentowpoddanych
radioterapii. 2. Odpowiedz na pytanie:
Czy istnieje zaleznosc mi~dzy poziomem
8-oksy-2' -deoksyguanozyny i 8-oksy-gua-
niny a odpowiedziq klinicznq na napro-
mienianie?
Material i metodyka: 29 pacjentow
z rozpoznaniem przerzutow do kosci,
jedno pole napromieniania 84 cm2-
104 cm2 na skorze, promienie X-250kV,
1 frakcja, dawka 10Gy. Materiatem do
badan byt mocz z DZM przed i po na-
promienieniu. Do probki 2 ml moczu
dodawano znakowanych izotopowo wzor-
cow {15N3, 13C}8-oksy-G i {180-8-oksy-
dG}. Oczyszczano metodq wysokospraw-
nej chromatografii cieczowej (HPLC), ze-
brane frakcje poddawano analizie iloscio-
wej za pomOCq chromatografii gazowej
ze spektometriq masowq (GC/MS).
Wyniki: 1. Stwierdzono spadek ilosci
8-oksyGua w DZM po radioterapii w sto-
sunku do ilosci 8-oksy-Gua przed napro-
mienianiem (p=0,002) 2.Nie stwierdzono
roznic znamiennych statystycznie w ilosci
8-oksydG. 3. W obu grupach chorych:
z poprawq i bez poprawy klinicznej,
zanotowano spadek wartosci 8-oksyGua
po radioterapii (p=O,01). 4. W grupie pa-
cjentow z poprawq klinicznq, stwierdzono
znamienny wzrost ilosci w DZM 8-oksydG.
Oznaczenia w grupie bez poprawy
klinicznej nie wykazafy roznic.
Wnioski: 1. Spadek i10sci wydalanej
w moczu 8~oksyGua po radioterapii moze
swiadczyc 0 tym, ze naprawa uszkodzen
DNA ulega regresji, a komorki Sq kie-
rowane na drog~ apoptozy. 2. Wzrost
zawartosci 8-oksydG w DZM, w grupie
z poprawq klinicznq, odzwierciedlatby
masywne obumieranie napromieniowa-
nych komorek guza i moze postuzyc jako
podstawa do opracowania prostego testu
prognostycznego promieniowrazliwosci ko-
morek nowotworowych.
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Objectives: Reactivation of telomerase
is believed to play an important role in
immortalization and carcinogenesis.
Design: To investigate the expression of
three components of telomerase complex
(hTR, hTERT, TP1) along with telomerase
activity in malignant and normal cells.
Methods: Cells isolated from gastric and
colon cancer, and normal mucosa from
stomach and colon of corresponding
patients. In addition established cell lines
from gastric and colon cancer have been
studied. Expression of hTERT, hTR and
TP1 has been studied by reverse tans-
criptase peR technique. Telomerase
repeat amplification protocol-TRAP and
PCR-ELISA was used for analysis
telomerase activity. FISH technique was
used to detect possible TERT gene
amplification.
Results: The all telomerase components
were consistently expressed in colon and
gastric cancer cells. Neoplastic RNA
produced consistently very strong ampli-
ication signals either for hTR hTERT and
TP1. The expression of hTR was observed
in RNA .isolated from all normal mucosa
samples and from peripheral blood
lymphocytes. The expression of TP1 and
hTERT has been found in the majority of
normal cells, however the amplification
signals produced were usually much
weaker then in malignant cells. The
limiting dilution experiments indicated that
the cancer cells have at least 100-fold
higher telomerase activity and at least
25-fold higher TP1 and hTERT expression
in comparison to normal cells. FISH
analysis revealed amplification of TERT
gene in malignant cells.
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Conclusions: It can be concluded that
all cancer cells tested have higher telo-
merase expression and activity, as com-
pared to normal cells. The high expression
and activity of telomerase in cancer cells
can be explained by amplified TERT gene.
Therefore telomerase can be a good
cancer marker provided quantitative
analysis is carried out. Grant support: The
work was sponsored by KSN grants No
4P05B 072 17 and 6P05E 102 20.
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Background: The erbS family of proto-
oncogenes (erbS-1, erbS-2, erbS-3, erbS-
4) and their receptors play an important
role in normal cell growth and neoplastic
transformation. Literature data indicate
that some abnormalities of erbS oncogene
play an important role in breast cancer
development, correlate with tumor aggre-
ssiveness and with worse clinical outcome.
Therefore, these abnormalities may poten-
tially have prognostic and therapeutic
relevance. Aim of the stUdy: To determine
the number of gene copies within erbS
oncogene family in breast cancer. The
relationship of abnormalities /CAln in the
dinucleotides and the loss of hetero-
zygosity (LOH) in erbS-1 were analyzed in
. relation to clinical and pathological fea-
tures of the tumors and to chemotherapy
response.
Matherials and methods: StUdy
subjects included 50 chemotherapy naive
LABC (any T, N2, any N, T4) patients
(pts). All pts received induction chemothe-
rapy. Tumor measurement was performed
after each cycle and at the completion
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of induction chemotherapy. Double diffe-
rential PCR (ddPCR) was used for de-
tection of erbS oncogene family abnor-
malities (gene amplification/deletion).
Microsatellite polymorphism of erbS-1 was
examined by PCR with fluorescently
labeled primers, followed by capillary
electrophoresis and quantitative analysis
of PCR product with GeneScanTM sys-
tem, using automated ASI PRSM 310.
Results: Amplifications of erbB-1, erbB-
2, erbB-3, erbB-4 (defined as AGCN value
of > 1.6) were detected in 5.9%, 26.5%,
2.9% and 2.9% of examined cases,
respectively. Deletions, defined as AGCN
value of < 0.4, accompanied only erbS-1
amplification and occurred in 26.5% of all
cases. There was a polymorphic simple
sequence repeat region of 12-20 CA
detected in the first intron of erbS-1.
Homozygotes comprised 31 % of the exa-
mined group. The majority of homozygous
pts revealed 14/14 CA repeat combination.
LOH (most frequently affecting shorter
allele) was determined in breast cancer
heterozygotes and occurred in 50%
of cases. Correlations between these fin-
dings and clinical outcomes will be pre-
sented.
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Objectives: The purpose of the study
was to evaluate the frequency of abnormal
DNA content in squamous cancer cells
(SCLC) and analyze its correlation with
late survival rates after surgical treatment.
Many previous studies included attempts
to associate DNA quantification with
prognosis for lung cancer. However, there
is still considerable divergence of opinion
about its prognostic value.
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